Advertisement

Topics

Latest "Zenobia Therapeutics" News Stories - Page: 20

06:54 EST 16th January 2019 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 476–500 of 8,300+

Probably Relevant

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL501 for Acute Treatment of Agitation

NEW HAVEN, Conn., Dec. 27, 2018 -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that the U.S. FDA has granted Fast Track Designation for its investigational drug BXCL501, a proprietary...


Revance Therapeutics' frown lines treatment succeeds in late-stage trial

Medical aesthetics company Revance Therapeutics Inc said on Tuesday that its long-acting injectable drug was successful in reducing moderate-to-severe frown lines in a late-stage study.

TG Therapeutics cancer trial setback sends shares tumbling

TG Therapeutics (TG) has suffered a setback in its blood cancer drug trial, as the data available was deemed not ready for analysis. The independent Data Safety Monitoring Board (DSMB) said that an interim analysis of the overall response rate (OR...


Small-Cap Snapshot: Pain Therapeutics shares rally after defying FDA rejection of lead drug

Small cap names on the move today are: Pain Therapeutics Inc (NASDAQ:PTIE), Casa Systems Inc's (NASDAQ:CASA), PetlQ Inc (NASDAQ:PETQ), Sigma Designs Inc (NASDAQ:SIGM). 

Global $85.5 Billion Precision Medicine (Diagnostics/Therapeutics) Market to 2025 - Key Players ...

DUBLIN, Nov. 16, 2018 /PRNewswire/ -- The "Precision Medicine (Diagnostics/Therapeutics) Market Analysis Report By Application (Genetic Tests, Esoteric Tests, Pharmaceuticals, Medical Devices), By End Use, Read more...

Protagonist Therapeutics nets $21.8mm via PIPE

Peptide therapies developer Protagonist Therapeutics Inc. netted $21.8mm through the sale of 2.75mm common shares at $8 each ...

Sarepta Therapeutics Enters Manufacturing Partnership With Paragon Bioservices

WASHINGTON (dpa-AFX) - Biopharmaceutical company Sarepta Therapeutics, Inc. (SRPT) said it has entered into a long-term strategic manufacturing partnership with Paragon Bioservices Inc.The manufac...

SEC Aims Insider Trading Charges at Former Sangamo Therapeutics Executive

The U.S. Securities and Exchange Commission has leveled charges at a former Sangamo Therapeutics Inc. executive and others for an insider-trading scheme that netted more than $1.5 million in “illegal profits.”

Neon Therapeutics nets $93mm through initial public offering

Neon Therapeutics Inc. (immuno-oncology) netted $93mm through its initial public offering of 6.25mm common shares at $16 (the...

G1 Therapeutics nets $195mm through public offering

G1 Therapeutics Inc. netted $195mm through the public sale of 3.45mm common shares (including the overallotment) at $60. The ...

Diverse pipeline for Type 2 diabetes therapeutics

Type 2 diabetes (T2DM) is a chronic and progressive metabolic disorder associated with many different complications. Patients require increasingly complex...Read More... The post Diverse pipeline for Type 2 diabetes therapeutics appeared first on Pharmaceutical Technology.

Karolinska Development AB (publ): Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational ...

Ovid Therapeutics Plans to Move into the Phase 3 Trial Based on End-of-Phase 2 Meeting for OV101

Ovid Therapeutics (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced plans to move ahead with a single pivotal Phase 3 trial of OV101 in pediatric patients with Angelman syndrome based on its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA). … Continued The pos...

Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 in Support of Benefit-Risk Profile of Zulresso (brexanolone) Injection for Treatment of Postpartum Depression

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 2, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S....

Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing

Sorrento Therapeutics (NASDAQ:SRNE) that its majority-owned subsidiary, Scilex Pharmaceuticals, closed a debt financing with leading global institutional investors for aggregate gross proceeds to Scilex of $140 million. As quoted in the press release: “This non-dilutive financing provides Scilex with the capital resources to successfully execute on the launch of ZTlido,” said Henry Ji, Chairma...

Nektar Therapeutics And Pfizer Enter Into New Clinical Oncology Collaboration

NEW YORK CITY (dpa-AFX) - Nektar Therapeutics (NKTR) said that it has entered into an oncology clinical collaboration with Pfizer Inc. (PFE) to evaluate several combination regimens in multiple ca...

Pluristem Therapeutics Announces FDA Orphan Drug Designation for PLX cell therapy

Pluristem Therapeutics (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company’s PLX cell therapy for the treatment of graft failure and incomplete hematopoietic recovery following hematopoietic cell transplantation...

Entasis Therapeutics and Principia Biopharma Join the IPO Queue

IPO activity has waned in the dog days of summer, but two more biotechs have now joined the growing list of companies with Wall Street ambitions. Entasis Therapeutics and Principia Biopharma have filed to go public, hoping to raise the cash needed to finance more clinical tests of their experimental drugs. Entasis and Principia each […]

PTC Therapeutics announces data from patient registry demonstrating Translarna slows disease progression in children with Duchenne caused by nonsense mutation

PTC Therapeutics, Inc announced preliminary data from the first international drug registry for Duchenne patients receiving Translarna (ataluren), underscoring the long─term clinical benefit of Translarna when

From Discovery To Trials In 18 Months: MD Anderson’s Therapeutics Discovery Team Approach

Clinical Informatics News | At MD Anderson, the Therapeutics Discovery team aims to develop new treatment options for MD Anderson patients in a much faster way. Two studies published in Nature Medicine earlier this month support the approach, they say.    

Nabriva Gains New CEO And Near-Market Antibiotic, Claims Leadership Role

The acquisition of Zavante Therapeutics and its late-stage investigational intravenous antibiotic for use in multi-drug resistant pathogens has also led...   

G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib

G1 Therapeutics (Nasdaq:GTHX), a clinical-stage oncology company, today announced positive topline data showing multi-lineage myelopreservation benefits in its randomized, double-blind, placebo-controlled Phase 2 trial evaluating trilaciclib in combination with topotecan as a treatment for 2nd-/3rd-line small cell lung cancer (2/3L SCLC). As quoted in the press release: “This is the third positi...

Tusk Therapeutics is acquired by Roche for $81M upfront

Immunotherapy developer Tusk Therapeutics was bought by Roche Holding for about $81 million upfront, and about $678 million i -More- 

InvestmentPitch Media Video Discusses FSD Pharma's New Cannabis Clinical Research Collaborative Program in Israel with R&D Partner SciCann Therapeutics - Video Available on Investmentpitch.com

Vancouver, British Columbia--(Newsfile Corp. - August 17, 2018) - FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTC Pink: FSDDF) has launched a, via its strategic R&D partner, SciCann Therapeutics Inc. T...

BTAI Up 105% In 5 Days, NVAX Gets A Shot In The Arm, BMY Snaps Up CELG

Today's Daily Dose brings you news about this year's first, and one of the biggest pharmaceuticals deals; BioXcel Therapeutics' Alzheimer's study results; CAS Medical's preliminary unaudited Q4 sales results; Catabasis Pharma's update on DMD trial; Marker Therapeutics' pipeline progress; and Novavax' phase II clinical trial results of NanoFlu.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks